Jasper Therapeutics, Inc. — Form 8-K Summary
Reporting date: June 6, 2024; filed June 12, 2024. The filing reports the company’s 2024 annual meeting and related equity-plan approvals, as well as executive employment agreements entered into on June 10, 2024. It does not provide quarterly or annual financial results.
Business Context and Corporate Actions
- Jasper Therapeutics is a Delaware biotechnology company listed on Nasdaq under JSPR and JSPRW.
- Stockholders approved the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan, both effective June 6, 2024.
- The company entered into amended and restated employment agreements with CEO Ronald Martell, CFO Herb Cross, COO Jeet Mahal, and CMO Edwin Tucker on June 10, 2024.
- The company terminated its Employee Severance Plan for Vice Presidents and Executive Committee Members in favor of individual executive agreements.
Financial Metrics and Liquidity
The filing text does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or financial guidance.
- CEO Ronald Martell’s annualized base salary is $727,272, with eligibility for a performance bonus of up to 50% of base salary.
- CFO Herb Cross’s annualized base salary is $476,100, with eligibility for a performance bonus of up to 45% of base salary.
- COO Jeet Mahal’s annualized base salary is $481,301, with eligibility for a performance bonus of up to 45% of base salary.
- CMO Edwin Tucker’s annualized base salary is $514,500, with eligibility for a performance bonus of up to 45% of base salary.
Material Changes and Compensation Provisions
- The CEO is entitled to 18 months of base salary and up to 18 months of COBRA premiums if terminated without Cause or resigns for Good Reason, subject to a release.
- If the CEO is terminated under those circumstances within 24 months following a change in control, severance increases to 18 months of base salary plus 1.5 times target incentive compensation; applicable equity awards may accelerate.
- Each of the CFO, COO, and CMO is entitled to 12 months of base salary and up to 12 months of COBRA premiums upon qualifying termination, subject to a release.
- Following a change in control, qualifying termination benefits for each of those executives include 12 months of base salary, 100% of target incentive compensation, and potential acceleration of applicable equity awards.
Annual Meeting Results
- 12,454,542 shares, representing approximately 82.6% of the 15,085,553 shares outstanding as of the April 11, 2024 record date, were represented.
- Ronald Martell and Christian W. Nolet were elected as Class III directors to serve until the 2027 annual meeting.
- Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2024.
- The 2024 Equity Incentive Plan was approved with 10,319,969 votes for, 95,298 against, and 7,488 abstentions, excluding broker non-votes.
- The 2024 ESPP was approved with 10,404,664 votes for, 12,102 against, and 5,989 abstentions, excluding broker non-votes.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no operating or financial outlook. Key matters for investors include potential future dilution and compensation expense from the approved equity plans, as well as substantial severance and equity-vesting obligations triggered by qualifying executive terminations, particularly following a change in control.
Important Facts to Verify
- Review the full 2024 Equity Incentive Plan and 2024 ESPP for share reserves, eligibility, and dilution provisions.
- Review the four executive employment agreements for complete definitions of Cause, Good Reason, and Change in Control.
- Assess potential severance, COBRA, bonus, and equity-acceleration obligations in future financial statements.
- Reconcile the filing’s June 6 report date with the June 10 employment-agreement dates and June 12 signature date.
- Use the company’s periodic reports for cash runway, operating expenses, research and development spending, debt, and other financial metrics not included in this 8-K.